Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
In FINCH 4, filgotinib 200 mg and 100 mg (continuous or de novo) demonstrated sustained efficacy up to week 156 in patients enrolled from FINCH 1, 2 or 3, with no unexpected safety results.
Authors
- Bernard Combe (ORCID: https://orcid.org/0000-0003-4002-1861)
- Vijay Rajendran
- Yoshiya Tanaka (ORCID: https://orcid.org/0000-0002-0807-7139)
- Edmund Omoruyi
- Paul Emery (ORCID: https://orcid.org/0000-0002-7429-8482)
- Francesco De Leonardis (ORCID: https://orcid.org/0000-0001-5801-7225)
- Roberto Caporali (ORCID: https://orcid.org/0000-0001-6331-8559)
- Anna Zubrzycka‐Sienkiewicz
- Maya H Buch (ORCID: https://orcid.org/0000-0002-8962-5642)
- Daniel Aletaha (ORCID: https://orcid.org/0000-0003-2108-0030)
- Hendrik Schulze‐Koops (ORCID: https://orcid.org/0000-0002-1681-491X)
- Tsutomu Takeuchi (ORCID: https://orcid.org/0000-0003-1111-8218)
- Ricardo Blanco (ORCID: https://orcid.org/0000-0003-2344-2285)
- Patrick Verschueren (ORCID: https://orcid.org/0000-0002-0340-3580)
- Jacques‐Eric Gottenberg (ORCID: https://orcid.org/0000-0002-9469-946X)
Institutions
- University of Leeds (GB)
- University of Occupational and Environmental Health Japan (JP)
- University of Milan (IT)
- Université de Montpellier (FR)
- Keio University (JP)
- University of Manchester (GB)
- NIHR Oxford Musculoskeletal Biomedical Research Centre (GB)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Marqués de Valdecilla University Hospital (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
- Istituto Ortopedico Gaetano Pini (IT)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
- Arthritis and Rheumatism Associates (US)
- NIHR Manchester Biomedical Research Centre (GB)
- Hôpital Civil, Strasbourg (FR)
- Université de Strasbourg (FR)
- Medical University of Vienna (AT)
- Ludwig-Maximilians-Universität München (DE)
- Galapagos (Belgium) (BE)
- Saitama Medical University (JP)
- KU Leuven (BE)
Publication Details
- Journal
- RMD Open
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/rmdopen-2024-004476
- Citations
- 4
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Celltrion
- Galápagos
- Eisai
- Astellas Pharma
- Nordic Pharma Group
- Samsung
- Pfizer Japan
- Chugai Pharmaceutical
- Eli Lilly Japan